STOCK TITAN

Aquestive Therapeutics (AQST) grants director 50,500 stock options at $3.99

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aquestive Therapeutics director Marco Taglietti received a grant of stock options covering 50,500 shares of common stock. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he remains in continuous service through that date.

Positive

  • None.

Negative

  • None.
Insider Taglietti Marco
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Purchase) 50,500 $0.00 --
Holdings After Transaction: Stock Option (Right to Purchase) — 50,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 50,500 options Grant of stock options to Marco Taglietti on June 10, 2026
Exercise price $3.99 per share Stock option exercise price for underlying common stock
Underlying shares 50,500 shares Common stock underlying the stock option award
Vesting date June 10, 2027 100% of underlying shares vest on this date with continuous service
Expiration date June 10, 2036 Option expiration for the granted stock options
Stock Option (Right to Purchase) financial
"security_title: Stock Option (Right to Purchase)"
exercise price financial
"conversion_or_exercise_price: 3.9900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"100% of the underlying shares vest June 10, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative securities financial
"transaction_type: derivative"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Taglietti Marco

(Last)(First)(Middle)
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Purchase)$3.9906/10/2026A50,50006/10/2027(1)06/10/2036Common Stock50,500$050,500D
Explanation of Responses:
1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Taglietti's continuous service with the Issuer from the grant date through the applicable vesting date.
Remarks:
/s/ Thomas Zalewski, as Attorney-In-Fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aquestive Therapeutics (AQST) report in Marco Taglietti’s latest Form 4?

Aquestive Therapeutics reported that director Marco Taglietti received a grant of stock options on June 10, 2026, for 50,500 shares of common stock. The filing details the exercise price, vesting schedule, and expiration date for this new equity award.

How many stock options did Marco Taglietti receive from Aquestive Therapeutics (AQST)?

Marco Taglietti received stock options covering 50,500 shares of Aquestive Therapeutics common stock. This derivative award was reported as a grant under transaction code A and represents his post-transaction derivative holdings according to the Form 4 data provided.

What is the exercise price of Marco Taglietti’s new Aquestive Therapeutics (AQST) options?

The new stock options granted to Marco Taglietti have an exercise price of $3.99 per share. This means he can purchase common stock at $3.99 once the options vest, subject to the terms and conditions disclosed for this award.

When do Marco Taglietti’s Aquestive Therapeutics (AQST) stock options vest and expire?

All 50,500 underlying shares vest on June 10, 2027, if Marco Taglietti maintains continuous service with Aquestive Therapeutics through that date. The options then remain exercisable until their stated expiration on June 10, 2036, according to the Form 4 footnote.

Is Marco Taglietti’s Form 4 transaction in Aquestive Therapeutics (AQST) a purchase or a grant?

The Form 4 reports a grant of stock options, not an open-market share purchase. The transaction is coded “A” for grant, award, or other acquisition and is described as a grant/award acquisition of derivative securities rather than a buy on the public market.

What conditions apply to the vesting of Marco Taglietti’s Aquestive Therapeutics (AQST) options?

Vesting of Marco Taglietti’s options requires continuous service with Aquestive Therapeutics. The footnote states that 100% of the underlying 50,500 shares vest on June 10, 2027, provided he remains in service from the grant date through that vesting date.